These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36919051)

  • 21. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
    Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
    Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of actinomycin D on ovarian reserve in low-risk gestational trophoblastic neoplasia.
    Xue W; Cang W; Zhao J; Feng F; Wan X; Ren T; Qiu L; Yang J; Xiang Y
    Int J Gynecol Cancer; 2023 Aug; 33(8):1222-1226. PubMed ID: 37290904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
    Lawrie TA; Alazzam M; Tidy J; Hancock BW; Osborne R
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD007102. PubMed ID: 27281496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
    Braga A; Biscaro A; do Amaral Giordani JM; Viggiano M; Elias KM; Berkowitz RS; Seckl MJ
    Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():50-55. PubMed ID: 29477553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of postmolar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective, secure and low-cost approach without adverse effects on compliance to general follow-up or subsequent treatment.
    Uberti EM; Fajardo Mdo C; da Cunha AG; Rosa MW; Ayub AC; Graudenz Mda S; Schmid H
    Gynecol Oncol; 2009 Aug; 114(2):299-305. PubMed ID: 19427681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia.
    Lybol C; Sweep FC; Harvey R; Mitchell H; Short D; Thomas CM; Ottevanger PB; Savage PM; Massuger LF; Seckl MJ
    Gynecol Oncol; 2012 Jun; 125(3):576-9. PubMed ID: 22410329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
    Chen YX; Shen YM; Qian JH; Xie X
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic toxicity following actinomycin D chemotherapy in treatment of familial gestational trophoblastic neoplasia: A case report.
    Mu X; Yin R; Wang D; Song L; Ma Y; Zhao X; Li Q
    Medicine (Baltimore); 2018 Sep; 97(38):e12424. PubMed ID: 30235719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fatal Cases of Gestational Trophoblastic Neoplasia in a National Trophoblastic Disease Reference Center in Dakar Senegal.
    Gueye M; Ndiaye-Gueye MD; Kane Gueye SM; Moreau JC
    Int J MCH AIDS; 2016; 5(1):32-8. PubMed ID: 27622010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-dose actinomycin D: Efficacy in the prophylaxis of postmolar gestational trophoblastic neoplasia in adolescents with high-risk hydatidiform mole.
    Uberti EM; Diestel MC; Guimarães FE; De Nápoli G; Schmid H
    Gynecol Oncol; 2006 Aug; 102(2):325-32. PubMed ID: 16476471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
    Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS
    Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of gestational trophoblastic neoplasia with 5-fluorouracil and actinomycin D in northern China.
    Zhao Y; Zhang W; Duan W
    J Reprod Med; 2009 Feb; 54(2):88-94. PubMed ID: 19301571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic Chemotherapy with Methotrexate Leucovorin in High-Risk Hydatidiform Mole.
    Aminimoghaddam S; Mahmoudzadeh F; Mohammadi M
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1755-1758. PubMed ID: 32592374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide.
    Braga A; Mora P; de Melo AC; Nogueira-Rodrigues A; Amim-Junior J; Rezende-Filho J; Seckl MJ
    World J Clin Oncol; 2019 Feb; 10(2):28-37. PubMed ID: 30815369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levels of serum anti-Müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis.
    Brouwer J; Laven JS; Hazes JM; Schipper I; Dolhain RJ
    Arthritis Care Res (Hoboken); 2013 Sep; 65(9):1534-8. PubMed ID: 23554429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia.
    Wang Q; Fu J; Hu L; Fang F; Xie L; Chen H; He F; Wu T; Lawrie TA
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD007289. PubMed ID: 28892119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of 5-day MTX and 5-day ETP treatment results and early predictors of drug resistance to 5-day MTX in patients with post-molar low-risk gestational trophoblastic neoplasia.
    Kizaki S; Hashimoto K; Matsui H; Usui H; Shozu M
    Gynecol Oncol; 2015 Dec; 139(3):429-32. PubMed ID: 26456138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1).
    McGrath S; Short D; Harvey R; Schmid P; Savage PM; Seckl MJ
    Br J Cancer; 2010 Mar; 102(5):810-4. PubMed ID: 20160727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uterine artery pulsatility index and serum BMP-9 predict resistance to methotrexate therapy in gestational trophoblastic neoplasia: A cohort study.
    Harvey RA; Elias KM; Lim A; Bercow A; Short D; Horowitz NS; Berkowitz RS; Agarwal R; Seckl MJ
    Curr Probl Cancer; 2021 Feb; 45(1):100622. PubMed ID: 32800689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia.
    Fu J; Fang F; Xie L; Chen H; He F; Wu T; Hu L; Lawrie TA
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD007289. PubMed ID: 23076934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.